TG Therapeutics TGTX Change In Fair Value Of Notes Payable
Change In Fair Value Of Notes Payable at other companies
Other financials
Where this comes from
Reported directly by TG Therapeutics in its filing.
Tagged under the XBRL concept tgtx:ChangeInFairValueOfNotesPayable.
The official record: TG Therapeutics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about TG Therapeutics's change in fair value of notes payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is TG Therapeutics's change in fair value of notes payable?
- TG Therapeutics (TGTX) reported change in fair value of notes payable of -$88K in Q1 2026.
- How has TG Therapeutics's change in fair value of notes payable changed year-over-year?
- TG Therapeutics's change in fair value of notes payable increased by 58.7% year-over-year, from -$213K to -$88K.
- What is the long-term trend for TG Therapeutics's change in fair value of notes payable?
- Over 2 years (2021 to 2024), TG Therapeutics's change in fair value of notes payable has grown at a -27.5% compound annual growth rate (CAGR), from $578K to -$304K.
- What does change in fair value of notes payable mean?
- The non-cash change in the value of debt due to market fluctuations.
- How do you interpret change in fair value of notes payable?
- An increase represents a non-cash expense or gain adjustment that does not impact immediate cash flow but reflects debt valuation changes.
- How does change in fair value of notes payable compare across companies?
- Common in companies with complex debt structures or convertible notes measured at fair value.